Effective testosterone suppression for prostate cancer: is there a best castration therapy?
Publication/Presentation Date
1-1-2009
Abstract
Achieving and maintaining effective suppression of serum testosterone levels in men treated with androgen ablation is one of the essential strategies in the management of prostate cancer. Historically, a serum testosterone below 50 ng/dL was considered to be the castrate level. Current data suggest that the new target for either surgical or chemical castration is a serum testosterone level of lower than 20 ng/dL in an attempt to maximize therapeutic outcomes. Testosterone breakthrough and the acute-on-chronic effects of administration of a luteinizing hormone-releasing hormone analogue may cause testosterone levels to periodically rise, sometimes to noncastrate levels. The goal of androgen ablation is to identify those agents that will most consistently achieve and maintain the lowest testosterone levels possible.
Volume
11
Issue
2
First Page
52
Last Page
60
ISSN
1523-6161
Published In/Presented At
Gomella L. G. (2009). Effective testosterone suppression for prostate cancer: is there a best castration therapy?. Reviews in urology, 11(2), 52–60.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
19680526
Department(s)
Administration and Leadership
Document Type
Article